TP53 and cancer: Given the known centrality of TP53 variants in cancers (TP53 somatic mutations have been observed in 96% of ovarian cancer samples [3]), this suggested to us that there could be a selection process occurring in these patients where variant TP53 is overexpressed or normal TP53 is suppressed or both.